Stealth Bio Shares Trading Higher On Pre-Clinical Presentation Of Neuromuscular Disease Candidate

Stealth BioTherapeutics MITO presented Pre-Clinical clinical results of SBT-272 for patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) at the Keystone Neurodegeneration Symposium in Keystone, held June 5-9, 2022.

The new SBT-272 preclinical data demonstrated functional improvement in upper motor neurons with TDP-43 pathology, playing a significant role in both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

A Phase 1 clinical study to evaluate the safety and tolerability of SBT-272 in healthy volunteers is underway.

Reenie McCarthy, Chief Executive Officer, said, "We designed SBT-272 to target mitochondrial dysfunction in the brain, which is known to precede and contribute to several neurodegenerative diseases, including ALS. We are encouraged that Dr. Ozdinler's team has elucidated these signals of neuronal protection, and we look forward to working with the ALS community to progress the clinical development of SBT-272."

The company stated that ALS is a devastating progressive neuromuscular disease with a significant unmet medical need.

Stealth BioTherapeutics shares are currently at $0.37, high 40 percent from its previous close of $0.27.

Posted In: Data PresentationBiotechPenny StocksHealth CareMovers & ShakersGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.